Evaluation of somatostatin inhibitory effect on pancreatic exocrine function using secretin-enhanced dynamic magnetic resonance cholangiopancreatography: a crossover, randomized, double blind, placebo-controlled study

What Was Tested

Researchers studied Secretin and Somatostatin in this randomized controlled trial publication.

Who Took Part

PubMed indexes the participants as adults, both men and women.

Ten healthy volunteers underwent 4 MRCP at a 1-week interval.

Pancreatic exocrine secretions were quantified by the measurements of pancreatic flow output and total excreted volume, derived from a linear regression between MRCP calculated volumes and time.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

Random assignment meant chance, not the researchers, decided who got Secretin and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Secretin, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Secretin could be set against what happens without it.

Each person switched between Secretin and the comparison at some point, usually with a gap in between.

MRCP was performed before and every 30 to 45 seconds for 15 minutes after secretin administration.

What Was Measured

PubMed files the paper under topics including Cholangiopancreatography, Magnetic Resonance, Pancreas, Exocrine, Secretin and Somatostatin.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Secretin and Somatostatin.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2006 (Pancreas), a journal based in United States.

More context: the Secretin compound page and the Somatostatin compound page, all human trials.